[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient’s combination of progressive sleep dysfunction (especially REM sleep behavior disorder and non-REM parasomnias), nocturnal stridor, gait instability, mild cognitive decline, and cerebellar atrophy on MRI is highly characteristic of **anti-IgLON5 disease**, a neurodegenerative disorder with prominent sleep-disordered breathing and parasomnias linked to IgLON5 autoantibodies.  \n\nThe other antibodies are associated with different syndromes:  \n- Anti-Hu → limbic encephalitis, peripheral neuropathy.  \n- Anti-Yo → paraneoplastic cerebellar degeneration.  \n- Anti-Ma2 → limbic/diencephalic/brainstem encephalitis.  \n- Anti-NMDA → acute psychiatric symptoms, seizures, dyskinesias, autonomic instability.  \n\nThus, the best option is **Anti-IgLON5 antibody**.  \n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has an intrauterine mass with intermediate trophoblastic cells, low mitotic activity, strong hPL positivity, and hCG negativity, which are classic features of placental site trophoblastic tumor (PSTT).  \nChoriocarcinoma shows biphasic trophoblastic proliferation and high hCG expression.  \nEpithelioid trophoblastic tumor also expresses hPL but typically has more epithelioid morphology and may express p63.  \nInvasive mole and persistent mole are characterized by villous structures and high hCG.  \n\nThe answer is B"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Danon disease is a severe X-linked disorder characterized by hypertrophic cardiomyopathy, skeletal myopathy, intellectual disability, and conduction abnormalities, often with multiple accessory pathways.  \nPatients are at high risk for malignant arrhythmias and sudden cardiac death, and catheter ablation in this setting carries a high recurrence rate and procedural risk due to the progressive nature of the disease.  \nGiven the severe hypertrophy, recurrent syncope, pre-excited atrial fibrillation despite medical therapy, and the underlying progressive cardiomyopathy, the most appropriate next step is evaluation for heart transplantation, which addresses both the arrhythmia risk and the advanced cardiomyopathy.  \n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has progressive multifocal leukoencephalopathy (PML) caused by JC virus reactivation, a known risk with natalizumab therapy, especially with a high JCV index and prolonged treatment.  \nIn natalizumab-associated PML, rapid removal of natalizumab via plasma exchange (or immunoadsorption) is critical to restore immune surveillance and improve survival.  \nOther options: continuing natalizumab would worsen PML; switching to ocrelizumab does not address urgent need to clear natalizumab; mirtazapine and mefloquine have been tried as adjunctive therapies but are not the most critical intervention for survival compared with restoring immune function.  \n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has a chronic urticarial rash, recurrent fevers, bone pain, monoclonal IgM kappa (indicating IgM gammopathy), and markedly elevated inflammatory markers, with symptoms refractory to antihistamines. This fits **Schnitzler syndrome**, a rare autoinflammatory disorder characterized by chronic urticaria, monoclonal IgM component, and systemic inflammation.  \n\nThe primary cytokine driver in Schnitzler syndrome is **interleukin-1 (IL-1)**, and treatment with IL-1 inhibitors (e.g., anakinra) typically leads to rapid and dramatic improvement.  \n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Cerebrotendinous xanthomatosis is caused by a deficiency of sterol 27-hydroxylase, leading to accumulation of cholestanol and cholesterol. The standard treatment is chenodeoxycholic acid supplementation, which downregulates cholesterol production and reduces cholestanol accumulation, preventing or halting neurologic progression.  \n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has a didelphic uterus (uterine duplication), right hematocolpos (blood-filled vagina), and ipsilateral renal agenesis. This triad is characteristic of **OHVIRA syndrome** (Obstructed Hemivagina with Ipsilateral Renal Agenesis), also known as Herlyn-Werner-Wunderlich syndrome.  \n\nThe answer is B"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient with a HeartMate 3 LVAD presents with signs of hemolysis (dark urine, elevated LDH, elevated plasma free hemoglobin) and evidence of inflow cannula obstruction on echo, along with increased power consumption with intermittent spikes — this suggests pump thrombosis.  \n\nFor **HeartMate 3**, which is a centrifugal pump with fully magnetically levitated technology, pump thrombosis is less common but can still occur. Inflow cannula obstruction can cause hemolysis and may be due to thrombus.  \n\nImmediate management for **suspected LVAD pump thrombosis** often involves consideration of **intrapump thrombolytics** (delivered directly into the pump via percutaneous catheter) as a potential bridge to surgery or definitive therapy, especially if the patient is stable enough for an attempt to avoid emergent surgery. Surgical pump exchange carries high morbidity/mortality, so guidelines often recommend considering thrombolysis first if no major contraindications exist.  \n\nAmong the options:  \n- **A** and **B** (increasing anticoagulation) are insufficient for acute pump thrombosis.  \n- **C** (intraventricular alteplase) is not the standard route; intrapump delivery is preferred.  \n- **D** (intrapump alteplase 10 mg via percutaneous catheter) is a recognized intervention for LVAD thrombosis.  \n- **E** (emergent surgical pump exchange) is definitive but higher risk; thrombolysis is often attempted first unless contraindicated or patient unstable.  \n\nGiven the acute presentation but without signs of irreversible shock or major bleeding contraindication, **intrapump thrombolysis** is the most appropriate immediate management before considering surgery.  \n\n**The answer is D**"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient is an immunocompetent gardener with subacute neurological symptoms, multiple ring-enhancing lesions on MRI, and lymphocytic pleocytosis in CSF.  \nGardening is a risk factor for **paragonimiasis** (lung fluke) or **neurocysticercosis**, but cysticercosis typically presents with single or few lesions, often with a scolex visible.  \nIn this case, multiple ring-enhancing lesions in an immunocompetent host with negative routine cultures raise concern for **neurocysticercosis** (often multiple cysts) or possibly **toxoplasmosis** (more common in immunocompromised).  \nHowever, the most appropriate empiric therapy for multiple neurocysticercosis with edema and mass effect is **albendazole plus steroids** (here miltefosine is not standard; but option B says albendazole plus miltefosine — miltefosine is used for amoebic meningoencephalitis, not cysticercosis).  \nGiven the options, only B includes albendazole, which is key for neurocysticercosis. Miltefosine is not standard but may be included in some protozoal co-treatment; however, in exam contexts, B is likely the intended answer for parasitic etiology.  \n\nOther options:  \nA) Liposomal amphotericin B – for fungal (e.g., cryptococcus, histoplasma) but not first choice here.  \nC) Vancomycin + ceftriaxone + dexamethasone – for bacterial brain abscess, but CSF cultures negative and subacute course not typical.  \nD) Ganciclovir + foscarnet – for CMV or HSV encephalitis, not ring-enhancing lesions typically.  \nE) Voriconazole – for aspergillosis or other molds, not most likely here.  \n\nGiven gardening exposure and multiple ring-enhancing lesions, neurocysticercosis is a leading possibility, and empiric albendazole with steroids (though steroid not explicitly in B) is appropriate. Miltefosine is unusual but may be a distractor.  \n\n**The answer is B**  \n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The condition described is deficiency of adenosine deaminase 2 (DADA2), a monogenic autoinflammatory disorder.  \nRecurrent fevers, livedo racemosa, lacunar strokes, and vasculitic neuropathy are classic features.  \nCurrent evidence shows that anti-TNF therapy (such as etanercept) is effective in preventing the vascular and inflammatory complications of DADA2, whereas glucocorticoids, cyclophosphamide, and rituximab are not first-line biologics for this condition, and anakinra (anti-IL-1) is less consistently effective than anti-TNF.  \n\nThe answer is C"}]